4.6 Review

Pyoderma gangrenosum: A review and update on new therapies

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2009.05.030

关键词

adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab

资金

  1. Galderma Laboratories LP

向作者/读者索取更多资源

Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies. (J Am Acad Dermatol 2010:62:646-54.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据